Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany

The aim of the study was to update previously published public health impact and cost-effectiveness analyses of the recombinant zoster vaccine (RZV), in the German population aged ≥50 years of age (YOA), with the latest vaccine efficacy (VE) estimates against herpes zoster (HZ). The updated estimate...

Descripción completa

Detalles Bibliográficos
Autores principales: Curran, Desmond, Van Oorschot, Desirée, Matthews, Sean, Hain, Johannes, Salem, Ahmed Ehab, Schwarz, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904019/
https://www.ncbi.nlm.nih.gov/pubmed/34905463
http://dx.doi.org/10.1080/21645515.2021.2002085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904019/
https://www.ncbi.nlm.nih.gov/pubmed/34905463
http://dx.doi.org/10.1080/21645515.2021.2002085

Ejemplares similares